⌘K

Login Start Free

Home/Filings/4/0000891293-16-000113

4//SEC Filing

CTI BIOPHARMA CORP 4

Accession 0000891293-16-000113

CIK 0000891293operating

View on SEC.gov Company Profile

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 6:30 PM ET

Size

21.3 KB

Accession

0000891293-16-000113

Insider Transaction Report

Form 4

Period: 2016-03-04

CTI BIOPHARMA CORPctic

Plunkett Matthew

EVP, Corporate Development

Transactions

Sale
Common Stock
2016-03-04$0.59/sh−1,500$882→ 596,248 total
Sale
Common Stock
2016-03-04$0.59/sh−700$413→ 594,704 total
Sale
Common Stock
2016-03-04$0.59/sh−700$414→ 594,004 total
Sale
Common Stock
2016-03-04$0.59/sh−200$118→ 593,804 total
Sale
Common Stock
2016-03-04$0.59/sh−1,100$652→ 592,704 total
Sale
Common Stock
2016-03-04$0.59/sh−500$297→ 592,204 total
Sale
Common Stock
2016-03-04$0.59/sh−1,220$726→ 590,984 total
Sale
Common Stock
2016-03-04$0.60/sh−900$536→ 590,084 total
Sale
Common Stock
2016-03-04$0.58/sh−1,300$761→ 598,784 total
Sale
Common Stock
2016-03-04$0.59/sh−400$234→ 598,384 total
Sale
Common Stock
2016-03-04$0.59/sh−636$373→ 597,748 total
Sale
Common Stock
2016-03-04$0.59/sh−844$497→ 595,404 total

Footnotes (1)

[F1]The sale was effected pursuant to a Rule 10b5-1 trading plan.

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT

Issuer

CTI BIOPHARMA CORP

CIK 0000891293

Entity typeoperating

IncorporatedDE

Related Parties

1

filerCIK 0000891293

Filing Metadata

Form type: 4
Filed: Mar 3, 7:00 PM ET
Accepted: Mar 4, 6:30 PM ET
Size: 21.3 KB

View on SEC.gov